Biography:Perry Nisen
Perry Nisen | |
|---|---|
 | |
| Born | July 27, 1955 New York, NY |
| Nationality | American |
| Alma mater | Stanford, Albert Einstein College of Medicine |
| Known for | Cancer drug discovery and development, clinical trial data sharing, deletions by transposons, X-recessive disorders in females, molecular genetics of human cancers |
| Scientific career | |
| Fields | Molecular Biology, Clinical Translation, Drug Discovery and Development, Clinical Data Sharing, Executive Management, Governance |
| Institutions | Sanford Burnham Prebys Medical Discovery Institute GlaxoSmithKline, Abbott Laboratories |
| Thesis | Flexible Genomes: Observations on the Rearrangement of DNA Sequences |
| Doctoral advisor | Stanley Norman Cohen (pre-doctoral), Lucy Shapiro(doctoral) |
Perry Nisen is an American physician and the former chief executive officer (CEO) of the Sanford Burnham Prebys Medical Discovery Institute (SBP).[1] He was appointed as CEO in August 2014, and held the Donald Bren Chief Executive Chair.[2]
Early life and education
- B.S. from Stanford University
- M.D. and Ph.D. from the Albert Einstein College of Medicine
- Residency, Columbia University College of Physicians and Surgeons[3]
Career
Before joining SBP, Nisen was Senior Vice President of Science and Innovation at GlaxoSmithKline (GSK). In this role, he facilitated innovation and integration of R&D across GSK's global organization and contributed to the discovery, development and commercialization of many drugs.[4] Earlier in his career at GSK, he held various key positions, including interim Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, and Senior Vice President of Clinical Pharmacology and Discovery Medicine.[5]
Nisen was Divisional Vice President of Cancer Research and Oncology Development at Abbott Laboratories, where he helped build a Cancer Discovery organization and created a pipeline of clinical candidates.[citation needed]
Formerly, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. He headed a basic research laboratory and was a practicing physician in pediatric hematology-oncology. He was a member of the Genetics and Development Graduate Training Program.[3]
Awards and honors
- Alpha Omega Alpha
- Macintosh Fellowship, Columbia University College of Physicians and Surgeons
- Basil O'Connor Research Award of the March of Dimes
- Lowe Foundation Professorship UT Southwestern
- Woodward Visiting Scholar, Harvard University[3]
References
- ↑ "Sanford Burnham Prebys CEO Perry Nisen Retiring in September". 2017-08-10. https://timesofsandiego.com/tech/2017/08/10/sanford-burnham-prebys-ceo-perry-nisen-retiring-in-september/.
- ↑ "Meet Sanford-Burnham's new CEO Perry Nisen". San Diego Union Tribune. 19 August 2014. http://www.sandiegouniontribune.com/news/science/sdut-cancer-drugs-sanford-nisen-2014aug19-story.html.
- ↑ 3.0 3.1 3.2 "Perry Nisen, M.D., Ph.D. - SBP". https://www.sbpdiscovery.org/team/perry-nisen-md-phd.
- ↑ Bender, Eric; Bender, E. (5 November 2015). "Q&A: Perry Nisen". Nature 527 (7576): S18. doi:10.1038/527S18a. PMID 26536220. Bibcode: 2015Natur.527S..18B.
- ↑ "Perry D. Nisen M.D., Ph.D.: Executive Profile & Biography". https://www.bloomberg.com/research/stocks/private/person.asp?personId=270538989&privcapId=4339276&previousCapId=277799796&previousTitle=INTELLIA%20THERAPEUTICS%20INC.
 |  |
